TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2023 Earnings Call Transcript August 1, 2023 8:30 AM ET
Company Participants
Jenna Bosco - Senior Vice President of Corporate Communications
Michael Weiss - Chairman, CEO and President
Adam Waldman - Chief Commercialization Officer
Sean Power - CFO, Corporate Secretary and Treasurer
Conference Call Participants
Eric Joseph - JP Morgan
Ed White - H.C. Wainwright
Roger Song - Jefferies
Mayank Mamtani - B. Riley Securities
Michael DiFiore - Evercore
Prakhar Agrawal - Cantor Fitzgerald
Matt Kaplan - Ladenburg Thalmann
Operator
Greetings, and welcome to the TG Therapeutics Second Quarter 2023 Financial Results and Business Update Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Jenna Bosco. Thank you, Ms. Bosco, you may begin.
Jenna Bosco
Thank you. Welcome, everyone, and thanks for joining us this morning. I am Jenna Bosco and with me today to discuss this morning's news of our ex-U.S. commercialization partner as well as the results for the second quarter of 2023 are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer.
Following our safe harbor statement, Mike will provide an overview of today's news as well as our corporate development. Adam will give an update on our commercialization efforts and Sean will provide a brief overview of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I'd like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, including sales performance, projected milestones and expectations for our marketed and pipeline products. TG cautions that these forward-looking statements are subject to risks that may cause our actual results to differ materially from those indicated. Factors that may affect TG Therapeutics' operations include various risk factors that can be found in our SEC filings.
In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. Today's conference call is being recorded for audio rebroadcast on TG's website, www.tgtherapeutics.com, where it will be available for the next 30 days.